'Special K' could relieve depression June 7, 201 Professor Colleen Loo (Medical
Xpress) -- Recreational drug and anaesthetic, ketamine, is being trialled in
people with severe depression and is providing almost instant relief from
symptoms, offering fresh hope of a quick new way to manage the illness at its
worst. Cooling Water Treatment - Merus Rings green solution to treat entire
cooling water systems - www.merusonline.com Ketamine, known colloquially as
“Special K”, has been shown to alleviate depression in a matter of minutes or
hours instead of the weeks it can take some conventional medications to treat
the illness. University
of New South Wales
researchers are leading the Australia-first clinical trial of ketamine to
determine if it could be the next frontier in treating depression, which
affects around 15 per cent of the population. Professor Colleen Loo, from
UNSW’s School of Psychiatry and the Black Dog Institute,
says while traditional antidepressant drugs remain useful, ketamine is
envisaged as an additional treatment option, not a replacement. “The magnitude of improvement we’re seeing within 24 hours is just
astounding compared to existing antidepressant treatments,” Professor Loo says.
“The only other antidepressant treatment
that comes anything close to it is electro-convulsive therapy, or ECT, the most
effective proven treatment for depression.” Researchers are investigating the
body’s response to ketamine by administering a range of small doses in the
placebo-controlled trial, given by intravenous infusion under careful medical
monitoring. Ketamine works on a different part of the brain from other
traditional antidepressants, which is helping researchers understand more about
the brain and its role in depression. “It’s a paradigm shift. All the
other existing antidepressant medications work on receptor systems like
serotonin, noradrenaline and dopamine, whereas this works on the glutamate
system,” Professor Loo says. A successful, ongoing trial could mean ketamine
will be used in Australia
in clinical settings within a decade. More information: Ketamine has so far
been successfully trialled on a handful of people, with more participants being
recruited. Anyone interested in participating in the trial should email
n.katalinic@unsw.edu.au , contact 02 9113 1637 or visit the Black Dog Institute
website for more information. Candidates
for the treatment are those adults with severe depression in need of medication
but who haven’t responded to traditional treatments.
No comments:
Post a Comment